Day One Biopharma Reports Director Changes and Executive Compensation Updates
Ticker: DAWN · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1845337
Sentiment: neutral
Topics: management-change, executive-compensation
TL;DR
Day One Biopharma shakes up board, adjusts exec pay.
AI Summary
On October 7, 2025, Day One Biopharmaceuticals, Inc. reported changes in its board of directors and executive compensation arrangements. Specifically, the company announced the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- October 7, 2025 (date) — Date of earliest event reported
- 1800 Sierra Point Parkway, Suite 200 Brisbane, California 94005 (location) — Principal executive offices address
- 001-40431 (other) — Commission File Number
FAQ
What specific roles have seen departures of officers?
The filing indicates the departure of certain officers but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states the election of directors but does not name the individuals in this summary section.
What are the key changes in compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers but does not detail the specific changes.
When was the date of the earliest event reported?
The date of the earliest event reported is October 7, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 1800 Sierra Point Parkway, Suite 200, Brisbane, California 94005.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2025-10-10 16:05:14
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
- $8.00 — ion with an exercise price per share of $8.00 or greater held by the directors and em
- $11.87 — h original exercise prices ranging from $11.87 to $23.41; Charles York, M.B.A., Chief
- $23.41 — exercise prices ranging from $11.87 to $23.41; Charles York, M.B.A., Chief Operating
- $21.14 — ucement grant with an exercise price of $21.14 which was not eligible for the Repricin
Filing Documents
- d41094d8k.htm (8-K) — 25KB
- 0001193125-25-237072.txt ( ) — 137KB
- dawn-20251007.xsd (EX-101.SCH) — 3KB
- dawn-20251007_lab.xml (EX-101.LAB) — 18KB
- dawn-20251007_pre.xml (EX-101.PRE) — 11KB
- d41094d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: October 10, 2025 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer